138 related articles for article (PubMed ID: 2132570)
1. Advances in macrocyclic gadolinium complexes as magnetic resonance imaging contrast agents.
Meyer D; Schaefer M; Doucet D
Invest Radiol; 1990 Sep; 25 Suppl 1():S53-5. PubMed ID: 2132570
[No Abstract] [Full Text] [Related]
2. Tolerance of extracellular contrast agents for magnetic resonance imaging.
Weinmann HJ; Press WR; Gries H
Invest Radiol; 1990 Sep; 25 Suppl 1():S49-50. PubMed ID: 2283256
[No Abstract] [Full Text] [Related]
3. Neurotoxicity of contrast media for magnetic resonance imaging after generalized breakdown of the blood-brain barrier.
Evill CA; Wilson AJ; Fletcher MC; Sage MR
Acad Radiol; 1996 Aug; 3 Suppl 2():S336-8. PubMed ID: 8796597
[No Abstract] [Full Text] [Related]
4. Paramagnetic liposomes as magnetic resonance contrast agents.
Unger E; Tilcock C; Ahkong QF; Fritz T
Invest Radiol; 1990 Sep; 25 Suppl 1():S65-6. PubMed ID: 2283260
[No Abstract] [Full Text] [Related]
5. Extravascular toxicity of two magnetic resonance contrast agents. Preliminary experience in the rat.
Cohan RH; Leder RA; Herzberg AJ; Hedlund LW; Wheeler CT; Beam CA; Nadel SN; Dunnick NR
Invest Radiol; 1991 Mar; 26(3):224-6. PubMed ID: 2055727
[TBL] [Abstract][Full Text] [Related]
6. Magnetic resonance imaging contrast enhancement versus tissue gadolinium concentration.
Wang SC; White DL; Pope JM; Brasch RC
Invest Radiol; 1990 Sep; 25 Suppl 1():S44-5. PubMed ID: 2283253
[No Abstract] [Full Text] [Related]
7. The synthesis and screening of nonionic gadolinium (III) DTPA-bisamide complexes as magnetic resonance imaging contrast agents.
Periasamy M; White D; deLearie L; Moore D; Wallace R; Lin W; Dunn J; Hirth W; Cacheris W; Pilcher G
Invest Radiol; 1991 Nov; 26 Suppl 1():S217-20; discussion S232-5. PubMed ID: 1667003
[No Abstract] [Full Text] [Related]
8. Quantification of capillary permeability to macromolecular magnetic resonance imaging contrast media in experimental mammary adenocarcinomas.
Brasch RC; Shames DM; Cohen FM; Kuwatsuru R; Neuder M; Mann JS; Vexler V; Mühler A; Rosenau W
Invest Radiol; 1994 Jun; 29 Suppl 2():S8-11. PubMed ID: 7928277
[No Abstract] [Full Text] [Related]
9. Theory of proton relaxation in solutions of magnetic nanoparticles, including the superparamagnetic size range.
Koenig SH; Kellar KE
Acad Radiol; 1996 Aug; 3 Suppl 2():S273-6. PubMed ID: 8796579
[No Abstract] [Full Text] [Related]
10. Safety of magnetic resonance imaging contrast agents.
Shellock FG; Kanal E
J Magn Reson Imaging; 1999 Sep; 10(3):477-84. PubMed ID: 10508312
[TBL] [Abstract][Full Text] [Related]
11. Magnetic resonance imaging enhanced with a macromolecular contrast agent. Detection of the zonal renal ischemia.
Vexler VS; Berthezene Y; Moseley ME; Brasch RC
Invest Radiol; 1991 Nov; 26 Suppl 1():S131-3; discussion S137-8. PubMed ID: 1808109
[No Abstract] [Full Text] [Related]
12. Rationale and applications for macromolecular Gd-based contrast agents.
Brasch RC
Magn Reson Med; 1991 Dec; 22(2):282-7; discussion 300-3. PubMed ID: 1725917
[No Abstract] [Full Text] [Related]
13. Magnetic resonance imaging contrast agents. Design and physicochemical properties of gadodiamide.
Chang CA
Invest Radiol; 1993 Mar; 28 Suppl 1():S21-7. PubMed ID: 8486500
[No Abstract] [Full Text] [Related]
14. The need for electron paramagnetic resonance and water exchange-rate data for understanding small magnetic resonance imaging contrast agents and their macromolecular complexes.
Koenig SH
Invest Radiol; 1994 Jun; 29 Suppl 2():S127-30. PubMed ID: 7928207
[No Abstract] [Full Text] [Related]
15. Experimental approach to the intra-arterial magnetic resonance imaging contrast media (Gd-DTPA-iodized oil) and new lipophilic gadolinium complex combined with iodized oil.
Yoshikawa K; Shiono T; Yamashita T; Iwai H; Abe O; Hisamatsu K; Takenaka E
Invest Radiol; 1994 Jun; 29 Suppl 2():S245-6. PubMed ID: 7928246
[No Abstract] [Full Text] [Related]
16. Spatial mapping of microvascular permeability and tissue blood volume using magnetic resonance imaging.
Demsar F; Roberts TP; Schwickert HC; Shames DM; van Dijke CF; Mann JS; Saeed M; Brasch RC
Acad Radiol; 1996 Aug; 3 Suppl 2():S344-6. PubMed ID: 8796599
[No Abstract] [Full Text] [Related]
17. The question of dose for gadolinium chelates in magnetic resonance imaging.
Runge VM; Kirsch JE; Wells JW; Dunworth JN; Woolfolk CE
Invest Radiol; 1994 Jun; 29 Suppl 2():S154-6. PubMed ID: 7928215
[No Abstract] [Full Text] [Related]
18. Brain distribution of MRI contrast media in rats after intracisternal injection.
Allard M; Kien P; Caille JM; Bonnemain B; Simonnet G
J Neuroradiol; 1987; 14(4):383-7. PubMed ID: 3131496
[No Abstract] [Full Text] [Related]
19. Experimental study of DOTA-gadolinium. Pharmacokinetics and pharmacologic properties.
Allard M; Doucet D; Kien P; Bonnemain B; Caillé JM
Invest Radiol; 1988 Sep; 23 Suppl 1():S271-4. PubMed ID: 3198361
[TBL] [Abstract][Full Text] [Related]
20. Gadolinium cryptelates as MR contrast agents.
Knop RH; Frank JA; Dwyer AJ; Girton ME; Naegele M; Schrader M; Cobb J; Gansow O; Maegerstadt M; Brechbiel M
J Comput Assist Tomogr; 1987; 11(1):35-42. PubMed ID: 3805426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
